- Global Pharma News & Resources

Astellas Promotes David Abbott to National Vice President Key Account Management

Astellas Promotes David Abbott to National Vice President Key Account Management

PR Newswire

NORTHBROOK, Ill., Aug. 16, 2018

NORTHBROOK, Ill., Aug. 16, 2018 /PRNewswire/ -- Astellas today announced that David Abbott has been promoted to national vice president Key Account Management (KAM). Abbott's previous role was senior director of Key Account Management for the company's Oncology franchise.

As National Vice President of KAM, Abbott will oversee teams who work with large healthcare organizations to provide educational resources and tools that help customers identify, educate and treat patients within therapeutic areas of interest to Astellas. Abbott joined Astellas in 2013.

"Astellas is deeply committed to delivering and creating value through products that serve our patients," said Percival Barretto-Ko, president, Astellas Americas. "I'm confident that David's deep experience, patient focus and track record at Astellas will position the company well as we build for the future."

Based in Massachusetts, Abbott brings more than 20 years of biopharma experience to his new role. Prior to joining Astellas, Abbott served as national access director at AVEO Oncology. He also held roles of increasing responsibility at Sanofi and Sanofi Genzyme, including regional sales manager for Hospital and Oncology, Oncology Access & Reimbursement account manager, and director of Multiple Sclerosis Payer and Channel Marketing.

Abbott holds a degree in Political Science from Providence College.

About Astellas
Astellas is a pharmaceutical company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. For more information on Astellas, please visit our website at You can also follow us on Twitter at @AstellasUS, Facebook at or LinkedIn at


View original content with multimedia:

SOURCE Astellas

Editor Details

  • Company:
    • PR Newswire
  • Website:
Last Updated: 16-Aug-2018